A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Clinical trial NCT05302284 · RECRUITING

Trial details

NCT number: NCT05302284
Sponsor: RemeGen Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Urothelial Carcinoma HER2-expressing

Start date: 2022-06-14
Primary completion: 2026-12-31
Enrollment: 452

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.